We love to hear from our listeners. Send us a message.

SR One Capital Management CEO Simeon George, M.D. has a seemingly innate ability to pick winning biotech builders. Early on, he and his firm got behind CRISPR's Samarth Kulkarni, Ph.D., Arcellx' Rami Elghandour, and Nkarta's Paul Hastings, for example. With nearly 50 biotech leaders in SR One's portfolio, there are plenty more where those three came from. On this episode of the Business of Biotech, Dr. George, admits that despite his gifted brain he more readily follows his heart. Still, over the course of our conversation, he shares insight into the decision making processes that have contributed to his success at picking winners as an investment banker and biotech venture capitalist. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: matt.pillar@lifescienceconnect.com

Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/